George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

    Go to full paper published in Journal of Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Academic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes: 

    Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.

    Go to full academic research paper from Clinical Epigenetics.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes: 

    Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.

    Go to full article published by Clinical OMICs.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    During the COVID-19 pandemic, some clinical trials have gone virtual.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:

    Treatment with pembrolizumab (brand name Keytruda) on its own shows modest responses in patients with recurrent ovarian cancer.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the International Journal of Surgery Case Reports curated by Editor in Chief George Lundberg, MD, who notes: 

    We present here an open-access case report and literature review of a patient with the H2K27M-mutant variant of diffuse midline glioma.

    Go to full paper published in the International Journal of Surgery Case Reports.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    This outline from the National Cancer Institute provides an overview of diffuse midline gliomas. Diffuse intrinsic pontine gliomas (DIPG), which occur primarily in children, are a subset of diffuse midline gliomas.